Celltaxis Aims to Revolutionize Lymphatic Disease Treatment by Targeting Underlying Biological Processes
Celltaxis, a company focused on lymphatic disease, is pursuing a novel therapeutic approach to restore lymphatic repair rather than merely managing symptoms. Current treatments for conditions like lymphedema and lipedema primarily involve compression garments, manual lymphatic drainage, and physical therapy, which help reduce swelling and improve quality of life but do not address the biological progression of the disease. Celltaxis's strategy involves developing oral small molecule therapies designed to target specific inflammatory pathways. Scientific research indicates that excessive levels of leukotriene B4 (LTB4), a potent inflammatory signaling molecule, can suppress the body's natural ability to repair damaged lymphatic vessels. This impairment leads to a cycle of chronic lymphatic dysfunction, contributing to swelling, fat deposition, tissue remodeling, and fibrosis. By selectively inhibiting leukotriene A4 hydrolase (LTA4H), the enzyme responsible for producing LTB4, Celltaxis aims to restore the ...
